What’s Propelling Kodiak Sciences Inc. (KOD) to Increase So Much?

The stock of Kodiak Sciences Inc. (NASDAQ:KOD) is a huge mover today! The stock increased 7.19% or $1.01 during the last trading session, reaching $15.06. About 187,486 shares traded or 10.38% up from the average. Kodiak Sciences Inc. (NASDAQ:KOD) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 9 months positive chart setup for the $570.13M company. It was reported on Sep, 13 by Barchart.com. We have $16.11 PT which if reached, will make NASDAQ:KOD worth $39.91M more.

Analysts await Kodiak Sciences Inc. (NASDAQ:KOD) to report earnings on November, 15. They expect $-0.33 earnings per share, up 75.19 % or $1.00 from last year’s $-1.33 per share. After $-0.31 actual earnings per share reported by Kodiak Sciences Inc. for the previous quarter, Wall Street now forecasts 6.45 % negative EPS growth.

More notable recent Kodiak Sciences Inc. (NASDAQ:KOD) news were published by: Fool.com which released: “The Smartest People on Wall Street Are Buying These 3 Stocks — Should You Follow? – Motley Fool” on February 27, 2019, also Prnewswire.com with their article: “Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019 – PRNewswire” published on May 09, 2019, Prnewswire.com published: “Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights – PRNewswire” on November 16, 2018. More interesting news about Kodiak Sciences Inc. (NASDAQ:KOD) were released by: Finance.Yahoo.com and their article: “Constellation Brands reports — What to know in markets Thursday – Yahoo Finance” published on April 03, 2019 as well as Finance.Yahoo.com‘s news article titled: “Do Institutions Own Shares In Kodal Minerals Plc (LON:KOD)? – Yahoo Finance” with publication date: August 01, 2019.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company has market cap of $570.13 million. The company's lead product candidate is KSI-301, a vascular endothelial growth factor -biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. It currently has negative earnings. The Company’s preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.